Results 211 to 220 of about 78,173 (258)

JAK inhibitors for rheumatoid arthritis

Expert Opinion on Investigational Drugs, 2023
JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo, Shingo Nakayamada, Yoshiya Tanaka   +2 more
openaire   +2 more sources

JAK inhibitors and black box warnings: what is the future for JAK inhibitors?

Expert Review of Clinical Immunology, 2023
Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune and myeloproliferative disorders. Recently, concern has arisen regarding their safety in patients with rheumatoid arthritis.Here, we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on ...
Kate Tokareva, Pankti Reid, Victor Yang, David Liew, Alexander C. Peterson, Aaron Baraff, Jon Giles, Namrata Singh   +7 more
openaire   +2 more sources

JAK inhibitors for the treatment of vitiligo

Journal of Dermatological Science
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged.
Shintaro, Inoue, Tamio, Suzuki, Shigetoshi, Sano, Ichiro, Katayama   +3 more
openaire   +2 more sources

JAK Inhibitor in CALR-Mutant Myelofibrosis

New England Journal of Medicine, 2014
na
PASSAMONTI, FRANCESCO, Caramazza, D., Maffioli, M.   +2 more
openaire   +6 more sources

[JAK inhibitor].

Nihon rinsho. Japanese journal of clinical medicine, 2013
Biologics targeting inflammatory cytokine has become a standardized tool for remission induction in rheumatoid arthritis (RA). However, it is handled under restricted conditions and their cost of acquisition is high. Small molecule drugs targeting Janus kinase (JAK), a molecule involved in intracellular signaling pathway has shown similar treatment ...
Kunihiro, Yamaoka, Yoshiya, Tanaka
openaire   +1 more source

JAK Protein Kinase Inhibitors

Drug News & Perspectives, 2005
In humans, the Janus protein tyrosine kinase family (JAKs) contains four members: JAK1, JAK2, JAK3 and TYK2. JAKs phosphorylate signal transducers and activators of transcription (STATs) simultaneously with other phosphorylations required for activation, and there are several cellular mechanisms in place to inhibit JAK/STAT signaling. That one might be
openaire   +2 more sources

Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases

International Immunopharmacology, 2023
Lianbao Ye
exaly  

JAK‐inhibitors for dermatomyositis: A concise literature review

Dermatologic Therapy, 2021
Aliza Paudyal
exaly  

Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis

Journal of Dermatological Treatment, 2022
Kevin Phan, Steven Phan
exaly  

<p>JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data</p>

Journal of Inflammation Research, 2020
R Conway, Robert Harrington
exaly